XBiotech

Update in progress

XBIT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies to treat disease. It advances a portfolio of product candidates targeting inflammatory and infectious diseases. The company is developing interleukin-1 alpha therapies for cancer, stroke, heart attack, arthritis, and related conditions. XBiotech was founded in 2005 and is based in Austin, Texas.

Company score

Sentiment: -0.49; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.32; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.31; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive